Life Healthcare Group Holdings Limited · JSE:LHC
Life Healthcare — Merger or Acquisition (January 2025)
18 slides from Life Healthcare's merger presentation, Jan 13, 2025
Slide 1: Disposal of Life Molecular Imaging
Disposal of Life Molecular Imaging Investor and Analyst Presentation 13 January 2025
Slide 2: Presentation Outline
PRESENTATION OUTLINE 1. Salient features of the transaction 2. Transaction rationale 3. Commercial aspects of the transaction 4. Life Healthcare strategy post transaction 5. Next steps & transaction timeline 2
Slide 3: Salient features of the transaction
01 Salient features of the transaction Chief Executive: Pete Wharton-Hood
Slide 4: Transaction Summary
TRANSACTION SUMMARY 1 • The disposal by Life Healthcare, through its wholly owned subsidiary Life Medical Group Limited (LMGL) of 100% of Life Molecular The transaction Imaging (LMI) to Lantheus Holdings Inc. (Lantheus) 2 Overview of the • Lantheus is a leading radiopharmaceutical-focused company wi
Slide 5: Transaction rationale
02 Transaction rationale Chief Executive: Pete Wharton-Hood
Slide 6: Transaction Rationale
TRANSACTION RATIONALE The transaction delivers a material unlock of value upfront, de-risking the execution of the LMI business plan while allowing shareholders to participate in the potential growth through future earnout, milestone and royalty payments ✓ Ability for shareholders to unlock • Opport
Slide 7: Who is Lantheus
WHO IS LANTHEUS Leading radiopharmaceutical-focused company PURPOSE Enable clinicians to • More than 65 years of improving patient care by making advancements across the healthcare spectrum Find, Fight and Follow disease to deliver better patient • Diversified portfolio and pipeline consists of ther
Slide 8: Commercial aspects of the transaction
03 Commercial aspects of the transaction CFO: Pieter van der Westhuizen
Slide 9: Purchase Consideration
PURCHASE CONSIDERATION In addition to the Purchase Consideration, Life Healthcare retains the right to Africa and net economic benefits to RM2 Purchase Consideration (US$m) RM2 and Africa licensing 50 125 50 In addition, as part of the 225 125 transaction, Life Healthcare 225 750 will retain: 350 ✓R
Slide 10: LMI Corporate Structure & Piramal Arrangement
LMI CORPORATE STRUCTURE & PIRAMAL ARRANGEMENT LMI Limited (UK) is owned by LMGL. A profit-sharing arrangement exists at LMGL, which covers profit generated by LMI as well as proceeds from a sale of the business Life Healthcare Group Holdings Limited Understanding the Piramal profit-sharing arrangeme
Slide 11: Net Proceeds to Life Healthcare
NET PROCEEDS TO LIFE HEALTHCARE Life Healthcare intends to return the net proceeds of the upfront payment to shareholders within 12 months of closing US$m Upfront Payment1 Potential Earnouts2 (Within 12 months of closing) (Between 2026 and 2034) Upfront payment 350 Est. earnout 1 (NeuraCeq USA sales
Slide 12: Life Healthcare strategy post transaction
04 Life Healthcare strategy post transaction Chief Executive: Pete Wharton-Hood
Slide 13: Who We Are | Our Portfolio – Southern Africa
WHO WE ARE | OUR PORTFOLIO – SOUTHERN AFRICA ACUTE DIAGNOSTICS¹ & RADIO PHARMA ▪ 71 healthcare facilities ▪2 cyclotrons ▪ Acute hospitals: ▪3 PET-CT sites ▪ 48 facilities ▪ 8 308 beds ▪7 imaging sites COMPLEMENTARY SERVICES HEALTHCARE SERVICES ▪ Mental health facilities: ▪ Employer based on-site ▪ 9
Slide 14: Life Healthcare Strategy
LIFE HEALTHCARE STRATEGY Grow and restructure our Expand complementary services Value-based acute network care contracting Imaging Innovative Facility Drive Mental Acute Renal contracting, and nuclear Oncology LHS PPPs optimisation underlying health rehab dialysis reimbursement medicine and growth a
Slide 15: Life Healthcare Strategy
LIFE HEALTHCARE STRATEGY ▪ Growth plans 2025/2026: ▪ 219 beds: ▪ 79 beds in FY2025 ▪ Commence build of 140 bed hospital Strong Growth ▪ Continued strong growth in Complementary services: ▪ Imaging transactions underway ▪ New PET-CT sites ▪ Renal Dialysis growth Drive asset ▪ Occupancies at 70% utili
Slide 16: Next steps & transaction timeline
05 Next steps & transaction timeline Chief Executive: Pete Wharton-Hood
Slide 17: Conclusion
CONCLUSION The transaction • Provides the ability for shareholders to unlock significant value • De-risks execution of the LMI business plan, through an acceleration of value • Enables shareholders to continue to participate in LMI growth going forward through milestone and royalty payments • Ensure
Slide 18: Thank you
Questions? Thank you LifO soci
Life Healthcare Group Holdings — Merger or Acquisition (January 2025) on 6ix